The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Recombinant Human Interleukin-1 Receptor Antagonist in Severe Traumatic Brain Injury: A Phase II Randomized Control Trial
Open accessAbstract
Traumatic brain injury (TBI) is the commonest cause of death and disability in those aged under 40 years. Interleukin-1 receptor antagonist (IL1ra) is an endogenous competitive antagonist at the interleukin-1 type-1 receptor (IL-1R). Antagonism at the IL-1R confers neuroprotection in several rodent models of neuronal injury (i.e., trauma, stroke and excitotoxicity). We describe a single center, phase II, open label, randomized-control study of recombinant human IL1ra (rhIL1ra, anakinra) in severe TBI, at a dose of 100 mg subcutaneously once a day for 5 days in 20 patients randomized 1:1. We provide safety data (primary outcome) in this pathology, utilize cerebral microdialysis to directly determine brain extracellular concentrations of IL1ra and 41 cytokines and chemokines, and use principal component analysis (PCA) to explore the resultant cerebral cytokine profile. Interleukin-1 receptor antagonist was safe, penetrated into plasma and the brain extracellular fluid. The PCA showed a separation in cytokine profiles after IL1ra administration. A candidate cytokine from this analysis, macrophage-derived chemoattractant, was significantly lower in the rh I Lira-treated group. Our results provide promising data for rhIL1ra as a therapeutic candidate by showing safety, brain penetration and a modification of the neuroinflammatory response to TBI by a putative neuroprotective agent in humans for the first time.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The chemokine system in diverse forms of macrophage activation and polarization
MANTOVANI, A., SICA, A., SOZZANI, S., ALLAVENA, P., VECCHI, A., & LOCATI, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.09.015 · Cited by 6,534
Classification of traumatic brain injury for targeted therapies
Saatman, K. E., Duhaime, A.-C., Bullock, R., Maas, A. I. R., Valadka, A., & Manley, G. T. (2008) · Journal of Neurotrauma · doi:10.1089/neu.2008.0586 · Cited by 1,141
Exploring new routes for neuroprotective drug development in traumatic brain injury
Janowitz, T., & Menon, D. K. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000330 · Cited by 74
Self-citation
Cited by
The far-reaching scope of neuroinflammation after traumatic brain injury
Simon, D. W., McGeachy, M. J., Bayır, H., Clark, R. S. B., Loane, D. J., & Kochanek, P. M. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.13 · Cited by 1,190
Blennow, K., Brody, D. L., Kochanek, P. M., Levin, H., McKee, A., Ribbers, G. M., Yaffe, K., & Zetterberg, H. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.84 · Cited by 634
Recent advances in traumatic brain injury
Khellaf, A., Khan, D. Z., & Helmy, A. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09541-4 · Cited by 485
Self-citationTraumatic Axonal Injury: Mechanisms and Translational Opportunities
Hill, C. S., Coleman, M. P., & Menon, D. K. (2016) · Trends in Neurosciences · doi:10.1016/j.tins.2016.03.002 · Cited by 306
Self-citationCellular infiltration in traumatic brain injury
Alam, A., Thelin, E. P., Tajsic, T., Khan, D. Z., Khellaf, A., Patani, R., & Helmy, A. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-02005-x · Cited by 297
Self-citationAnakinra Therapy for Non-cancer Inflammatory Diseases
Cavalli, G., & Dinarello, C. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01157 · Cited by 292
Systemic inflammation after stroke: implications for post‐stroke comorbidities
Simats, A., & Liesz, A. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202216269 · Cited by 276
Inflammation in epileptogenesis after traumatic brain injury
Webster, K. M., Sun, M., Crack, P., O’Brien, T. J., Shultz, S. R., & Semple, B. D. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0786-1 · Cited by 274
Emerging Roles for the Immune System in Traumatic Brain Injury
McKee, C. A., & Lukens, J. R. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00556 · Cited by 263
Yang, Y., Ye, Y., Kong, C., Su, X., Zhang, X., Bai, W., & He, X. (2019) · Neurochemical Research · doi:10.1007/s11064-018-02714-z · Cited by 194
Activation of NLRP3 inflammasome enhances the proliferation and migration of A549 lung cancer cells
WANG, Y., KONG, H., ZENG, X., LIU, W., WANG, Z., YAN, X., WANG, H., & XIE, W. (2016) · Oncology Reports · doi:10.3892/or.2016.4569 · Cited by 186
Metadata
- Authors
- Helmy, A., Guilfoyle, M. R., Carpenter, K. L., Pickard, J. D., Menon, D. K., & Hutchinson, P. J.
- Venue
- Journal of Cerebral Blood Flow & Metabolism
- Publisher
- SAGE Publications
- Published
- 2014-02-26
- Volume
- 34
- Issue
- 5
- Pages
- 845-851
- ISSN
- 0271-678X (ISSN-L)
- 1559-7016
- OpenAlex
- W2092108542
- Cited by
- 182
- References
- 3
- FWCI
- 11.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.